HH101785 is a potent and highly selective PARP1 inhibitor. Currently marketed first-generation PARP inhibitors generally lack selectivity, simultaneously inhibiting both PARP1 and PARP2, which leads to significant hematological and other toxicities in clinical applications, thereby limiting their widespread use. HH101785 strongly inhibits PARP1 enzymatic activity with over 1000-fold selectivity for PARP1 versus PARP2 and other PARP family members. Compared to first-generation PARP inhibitors and second-generation competitors, it demonstrates markedly reduced hematological toxicity and a wider therapeutic window for antitumor treatment. Combined with its favorable drug metabolism and pharmacokinetic profile, HH101785 holds broad prospects for clinical application.

Haihe Biopharma Co., Ltd. is a global, innovation-driven biopharmaceutical company headquartered in China, with operational hubs in the United States and Japan. The company is dedicated to the development of cutting-edge anti-cancer therapies. With fully integrated capabilities spanning drug discovery, development, manufacturing, and commercialization, Haihe Biopharma aims to deliver life-saving treatments to cancer patients around the world and features a globally minded management and R&D team focused on in-house innovation. Currently, Haihe Biopharma has two approved products: Gumarontinib (INN), approved in both China and Japan, and paclitaxel oral solution (RMX3001/DHP107), approved in China, along with a robust pipeline of additional drug candidates.